Epistaxis or epiphora as a sign for extension of a conjunctival melanoma. A series of six patients with nasolacrimal recurrence

British Journal of Ophthalmology

Volumn 94, Issue 10, 2010, Pages 1328-1331

  Missotten, G S ^a,b,c   Gambrelle, J ^d   De Wolff Rouendaal, D ^a   De Keizer, R J W ^a,e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VIRGA JESSE HOSPITAL   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d HOSPICES CIVILS DE LYON   (France)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RECURRENCE; CONJUNCTIVA TUMOR; CONJUNCTIVAL MELANOMA; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; EPIPHORA; EPISTAXIS; EVISCERATION; EYE TUMOR; FEMALE; FOLLOW UP; HUMAN; LACRIMAL DUCT; MAJOR CLINICAL STUDY; MALE; MELANOSIS; METASTASIS; NASOLACRIMAL MELANOMA; PREVALENCE; PRIMARY ACQUIRED MELANOSIS; PRIORITY JOURNAL; RADIATION DOSE; RECURRENCE RISK; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; CONJUNCTIVAL NEOPLASMS; EPISTAXIS; EYE NEOPLASMS; FATAL OUTCOME; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LACRIMAL APPARATUS DISEASES; MALE; MELANOMA; MIDDLE AGED; NASOLACRIMAL DUCT; RECURRENCE;

EID: 77958586360     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.168823     Document Type: Article

References (22)

1. Seregard S. Conjunctival melanoma: major review. Surv Ophthalmol 1998;42:321-50.
2. Missotten GS, Keijser S, de Keizer RJW, et al. Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci 2005;46:75-82. (Pubitemid 40041181)
3. Tuomaala S, Eskelin S, Tarkkanen A, et al. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci 2002;43:3399-408. (Pubitemid 35334346)
4. Werschnik C, Lommatzsch PK. Long-term follow-up of patients with conjunctival melanoma. Am J Clin Oncol 2002;25:248-55. (Pubitemid 34602545)
5. Inskip PD, Devesa SS, Fraumeni JF. Trends in the incidence of ocular melanoma in the United States, 1974-1998. Cancer Causes Control 2003;14:251-7.
6. Triay E, Bergman L, Nilsson B, et al. Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol. Published Online First: 2009.
7. Kujala E, Tuomaala S, Eskelin S, et al. Mortality after uveal and conjunctival melanoma: which tumour is more deadly? Acta Ophthalmol 2009;87:149-53.
8. Shields CL. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Trans Am Ophthalmol Soc 2000;98:471-92.
9. Lommatzsch PK. Beta-Ray treatment of malignant epibulbar melanoma. Graefe Arch Klin Exp Ophthalm 1978;15:111-24.
10. Shields JA, Shields CL, Freire JE, et al. Plaque radiotherapy for selected orbital malignancies: preliminary observations: the 2002 Montgomery Lecture, part 2. Ophthal Plast Reconstr Surg 2003;19:91-5.
11. Damato B, Coupland SE. An audit of conjunctival melanoma treatment in Liverpool. Eye 2009;23:801-9.
12. De Keizer RJW, Schimmel EC. Iridium-192 brachytherapy of eyelid, conjunctiva and orbital malignancies. Abstracts of the International Society of Ocular Oncology Meeting Amsterdam 2001;46.
13. Pe'er J, Frucht-Pery J. The treatment of primary acquired melanosis (PAM) with atypia by topical mitomycin C. Am J Ophthalmol 2005;139:331-2.
14. Robertson DM, Hungerford JL, McCartney A. Malignant melanomas of the conjunctiva, nasal cavity, and paranasal sinuses. Am J Ophthalmol 1989;108:440-2.
15. de Wolff-Rouendaal D. Conjunctival melanoma in The Netherlands: a clinicpathological and follow-up study. Thesis. All In BV;Katwijk 1990.
16. Paridaens ADA, McCartney ACE, Lavelle RJ, et al. Nasal and orbital recurrence of conjunctival melanoma 21 years after exenteration. Br J Ophthalmol 1992;76:369-71.
17. Gökmen SH, Ardic F. Malignant conjunctival tumours invading the orbit. Ophthalmologica 2008;222:338-43.
18. McNab AA, McKelvie P. Malignant melanoma of the lacrimal sac complicating primary acquired melanosis of the conjunctiva. Ophthalmic Surg Lasers 1997;28:501-4.
19. Kurli M, Finger PT. Topical mitomycin chemotherapy for conjunctival acquired melanosis with atypia: 12 years' experience. Graefes Arch Clin Exp Ophthalmol 2005;243:1108-14.
20. Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol 2006;90:819-22.
21. Tuomaala S, Aine E, Saari M, et al. Corneally displaced malignant conjunctival melanomas. Ophthalmology 2002;109:914-19.
22. Weiss JS, Perusse P, Reale F. Tear cytology in conjunctival melanoma. Am J Ophthalmol 1991;111:648-92.